ANTHEM vs PAR: Stock Comparison

Anthem Biosciences Limited vs Par Drugs And Chemicals Limited

Live data: 24 July 2026, 4:08 PM IST • Source: NSE and company filings

Anthem Biosciences Limited is the larger company by market capitalisation. Anthem Biosciences Limited shows a higher ROE, a higher dividend yield and faster revenue growth, while Par Drugs And Chemicals Limited shows a lower P/E and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Anthem Biosciences Limited and Par Drugs And Chemicals Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, ANTHEM is more favourable on 9 of 13 scored metrics and PAR on 4These counts are context-free and are not an overall rating.

Key Differences

Market Cap
ANTHEM is the larger company
₹43,398 Cr vs ₹116 Cr
P/E Ratio
PAR has a lower P/E
8.55x vs 75.11x
P/B Ratio
PAR has a lower P/B
0x vs 14.22x
EPS
PAR has higher earnings per share
₹10.65 vs ₹10.13
Dividend Yield
ANTHEM has a higher dividend yield
0.25% vs 0%
Revenue Growth (TTM YoY)
ANTHEM has faster revenue growth
26.4% vs -12.2%
EPS Growth (TTM YoY)
ANTHEM has faster EPS growth
127.2% vs -48.5%
Qtr Sales Growth
ANTHEM has stronger quarterly sales growth
26.4% vs -12.2%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricANTHEMPAR
SectorHealthcareHealthcare
IndustryBiotechnologyPharmaceuticals

Price

MetricANTHEMPAR
Live Price₹769.9₹93.79
Day Change-1.02%-2.48%
Volume2.43 L12,063
52-Week High₹873.5₹114
52-Week Low₹579.15₹78.05
Distance from 52W High-11.86%-17.73%

Valuation

MetricANTHEMPAR
Market Cap₹43,398 Cr₹116 Cr
P/E Ratio75.11x8.55x
P/B Ratio14.22x0x
EPS₹10.13₹10.65
Book Value₹54.17₹90.52
Dividend Yield0.25%0%

Growth

MetricANTHEMPAR
Revenue Growth (TTM YoY)26.4%-12.2%
EPS Growth (TTM YoY)127.2%-48.5%
Qtr Sales Growth26.4%-12.2%
Qtr Profit Growth129%-48.5%

Profitability & Leverage

MetricANTHEMPAR
ROE22.3%12.4%
ROCE30.4%16.5%
Net Margin26.05%12.65%
Operating Margin39.3%16.5%
Debt to Equity0.02x0x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricANTHEMPAR
Promoter Holding71.42% 3.26 pp73.41%
FII Holding2.58% 1.3 pp0%
DII Holding13.48% 1.93 pp0.09% 0.09 pp
Public Holding12.53% 0.03 pp26.51% 0.08 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Anthem Biosciences Limited and Par Drugs And Chemicals Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.